Literature DB >> 33339720

Clinical and radiologic comparison of anterior-posterior single-position lateral surgery versus MIS-TLIF for degenerative lumbar spondylolisthesis.

Yoshihisa Kotani1, Yoshinao Koike2, Atsushi Ikeura3, Hirohiko Tokunaga3, Takanori Saito4.   

Abstract

BACKGROUND: The lateral interbody fusion (LIF) has gained popularity for the surgical treatment of lumbar degenerative spondylolisthesis (DS), however, LIF often requires the position change for posterior screwing. We have performed the single-position lateral surgery of oblique lateral interbody fusion (OLIF) and posterior screwing (OLIF-LPF). The present study compared the clinical and radiologic results between OLIF-LPF and minimally invasive transforaminal interbody fusion (MIS-TLIF).
METHODS: A total of 142 patients underwent either OLIF-LPF (92 cases) or MIS-TLIF (50 cases) for L3 or L4 DS. The average age was 72 and 70 years old, respectively. The OLIF-LPF was performed in right decubitus position with allograft and percutaneous modified cortical bone trajectory screws (mCBT). The MIS-TLIF utilized a single 4 cm midline incision, allograft, boomerang cage and mCBTs. The operation time, estimated blood loss, and serum CRP levels were recorded. JOABPEQ effectiveness rate (%), Visual Analogue Scale (VAS), fusion rate, segmental radiologic alignment, and complications were also evaluated.
RESULTS: Average follow-up period was 31 and 57 months in OLIF-LPF and MIS-TLIF, respectively. The average operation time and estimated blood loss were 108min, 51 ml and 104 min and 69 ml, respectively. OLIF-LPF demonstrated significantly higher values of mental health domain of JOABPEQ effectiveness rate and VAS improvement of leg pain than those in MIS-TLIF. The less correction loss of posterior disc height was demonstrated in OLIF-LPF. The fusion rate and symptomatic adjacent segment degeneration (ASD) were statistically equivalent between two groups.
CONCLUSIONS: The single-position surgery of OLIF combined with posterior screwing serves as a safe, minimally invasive and effective surgical modality without the need of position change. It provides comparable fusion rate, segmental radiologic alignment, and symptomatic adjacent segment degeneration to MIS-TLIF surgery.
Copyright © 2020 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.

Entities:  

Year:  2020        PMID: 33339720     DOI: 10.1016/j.jos.2020.10.013

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  5 in total

1.  Efficacy of Single-Position Oblique Lateral Interbody Fusion Combined With Percutaneous Pedicle Screw Fixation in Treating Degenerative Lumbar Spondylolisthesis: A Cohort Study.

Authors:  Peng Cheng; Xiao-Bo Zhang; Qi-Ming Zhao; Hai-Hong Zhang
Journal:  Front Neurol       Date:  2022-06-15       Impact factor: 4.086

2.  Comparison of Oblique Lateral Interbody Fusion (OLIF) and Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI-TLIF) for Treatment of Lumbar Degeneration Disease: A Prospective Cohort Study.

Authors:  Hai-Feng Zhu; Xiang-Qian Fang; Feng-Dong Zhao; Jian-Feng Zhang; Xing Zhao; Zhi-Jun Hu; Shun-Wu Fan
Journal:  Spine (Phila Pa 1976)       Date:  2022-03-15       Impact factor: 3.241

3.  Meta-Analysis of the Clinical Effect of MIS-TLF Surgery in the Treatment of Minimally Invasive Surgery of the Orthopaedic Spine.

Authors:  Wanliang Yang; Xin Pan; Xun Xiao
Journal:  Comput Intell Neurosci       Date:  2022-03-16

4.  Comparative analysis of the effects of OLIF and TLIF on adjacent segments after treatment of L4 degenerative lumbar spondylolisthesis.

Authors:  Guang-Qing Li; Tong Tong; Lin-Feng Wang
Journal:  J Orthop Surg Res       Date:  2022-04-04       Impact factor: 2.359

5.  Posterior Oblique Square Decompression with a Three-Step Wanding Technique in Tubular Minimally Invasive Transforaminal Lumbar Interbody Fusion: Technical Report and Mid-Long-Term Clinical Outcomes.

Authors:  Takashi Tomita; Keita Kamei; Ryota Yamauchi; Takahiro Nakagawa; Hirotsugu Omi; Yoshiro Nitobe; Toru Asari; Gentaro Kumagai; Kanichiro Wada; Junji Ito; Yasuyuki Ishibashi
Journal:  J Clin Med       Date:  2022-03-16       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.